Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Unprecedented smoking cessation levels seen in alpha-1 patients

By Mindo - 18th Nov 2019 | 19 views

A new Irish study has found that a diagnosis of alpha-1 antitrypsin deficiency (AATD), regardless of severity, leads to long-term smoking cessation, with higher quit levels seen than among patients with lung cancer or chronic obstructive pulmonary disease (COPD).

The new research, conducted with the help of participants in the National AATD Registry at Beaumont Hospital, Dublin, found that just 2 per cent of smokers with the most severe type of AATD continued smoking after diagnosis, while 16 per cent of those with less severe types of the deficiency continued to smoke.

These figures contrast starkly with quit levels among smokers diagnosed with lung cancer or COPD, where large numbers of patients continue smoking, research shows.

The study findings coincide with updated figures from the national-targeted AATD screening programme, which began 15 years ago, and provide new insights into Ireland’s AATD population. Ireland has one of the highest rates in the world of AATD, a rare genetic disorder which can lead to COPD, liver disease, and premature death.

Dr Alessandro Franciosi, Clinical Lecturer at the RCSI — who carried out the research with Dr Tomás Carroll, Chief Scientist at the Alpha-1 Foundation Ireland and Senior Lecturer at the RCSI — told the Medical Independent that testing for AATD should be much more widespread in Ireland to prevent disease and should be offered to all patients diagnosed with COPD, as per World Health Organisation  guidelines.

With this mild form of the disorder, people are only at-risk of lung disease if they smoke.

According to Dr Carroll, the HSE’s national smoking cessation programme, which he describes as one of the best in the world, could be used to communicate this message to smokers, helping to prevent or postpone lung disease in high-risk smokers with AATD.

The research was presented at the recent Alpha-1 Foundation Conference in Dublin.

Leave a Reply

Latest Issue
The Medical Independent 30th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read